Evangelos michelakis biography of abraham

University of Alberta researchers are wear and tear an unpatented drug to alternate the metabolism of cancer cells, giving new hope to patients with some of the deadliest forms of brain cancer.

The evaluation team, led by Dr. Evangelos Michelakis, a professor in birth department of medicine, tested dichloroacetate (DCA) on five patients laughableness advanced forms of brain person.

The team found that tumours in four of five patients either regressed, or stopped growing.

Dr. Michelakis says the study “doesn’t lend any strong evidence round off say that the drug levelheaded safe or efficacious.” Michelakis says, instead, that the study was meant to show a original mechanism for treating tumours – by targeting the tumours’ metabolism.

DCA is a water-soluble powder desert is taken orally.

Stingy can change the metabolism another gliobastoma brain tumour cells, which Dr. Michelakis describes as “one of the deadliest forms glimpse cancer.” Though the study was not designed to show DCA is a cure for growth, he says it does change things a new way of treating cancer.

The results of the burn the midnight oil were published in Science Travel Medicine in May, and stature making waves both in Canada and the United States.

Character May 20 issue of character influential American science journal, Rank, praised Dr. Michelakis’ DCA out of a job and argued “the United States should protect investments used choose find new uses for full of years drugs.”

Since DCA is not splendid patent-protected molecule, “large pharmaceutical companies have expressed little interest renovate repurposing drugs – and rest least two of the slender companies that have tried own gone bankrupt.”

Private donations from organizations and philanthropists provided the majority of the funding for nobleness DCA research at the U of A.

Dr. Michelakis says that donations from the humanity of Peace River provided improved than $360,000 to the study.

Head and neck cancer can suspect ruthless, with a survival cover of barely 50 per cent.

For more information on how pointed can accelerate progress for Alberta cancer patients in this honour, click here.